Alan K. Burnett

4.6k citations

35 papers · 2.3k indexed · h-index 23

Hematology top 0.5%
- Acute Myeloid Leukemia Research 21
- Chronic Myeloid Leukemia Treatments 5
- Multiple Myeloma Research and Treatments 3
Genetics top 2%
- Chronic Lymphocytic Leukemia Research 6
Public Health, Environmental and Occupational Health top 5%
- Acute Lymphoblastic Leukemia research 11
Molecular Biology top 10%
- Retinoids in leukemia and cellular processes 6
- Histone Deacetylase Inhibitors Research 3
Oncology top 10%
- Neutropenia and Cancer Infections 3

Co-authors: Robert K. Hills Keith Wheatley David C. Linch Rosemary E. Gale Anthony H. Goldstone Richard L. Darley Richard E. Clark Alastair G. Smith
Cited by: Hematology Genetics Public Health, Environmental and Occupational Health
Journals: Blood (14 papers)Biochemical and Biophysical Research Communications (1 paper)British Journal of Haematology (7 papers)
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Alan K. Burnett

35 papers receiving 2.3k citations

Peers

Countries citing papers authored by Alan K. Burnett

Since Specialization

Citations

This map shows the geographic impact of Alan K. Burnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan K. Burnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan K. Burnett more than expected).

Fields of papers citing papers by Alan K. Burnett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan K. Burnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan K. Burnett. The network helps show where Alan K. Burnett may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alan K. Burnett, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan K. Burnett Line = papers co-authored together Alan K. Burnett links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center Leukemia ·Roland B. Walter,Megan Othus,Alan K. Burnett,Bob Löwenberg,H. Kantarjian,Gert J. Ossenkoppele,Robert K. Hills,Farhad Ravandi,Thomas Pabst,Anna Evans,Sherry R. Pierce,Marie‐Christiane Vekemans,Frederick R. Appelbaum,Elihu H. Estey	2014	116
2	Does BCR/ABL1 positive Acute Myeloid Leukaemia Exist? British Journal of Haematology ·E Nacheva,Colin Grace,Diana Brazma,Katya Gancheva,Julie Howard‐Reeves,Lena Rai,Rosemary E. Gale,David C. Linch,Robert K. Hills,Nigel H. Russell,Alan K. Burnett,Panagiotis Kottaridis	2013	42
3	CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia Leukemia ·Steven Coles,Eddie C. Y. Wang,Stephen Man,Robert K. Hills,Alan K. Burnett,Alex Tonks,Richard L. Darley	2011	141
4	Applicability of a “Pick a Winner” trial design to acute myeloid leukemia Blood ·Robert K. Hills,Alan K. Burnett	2011	58
5	"No decisions about us without us"? Individual healthcare rationing in a fiscal ice age BMJ ·J. Russell,Trisha Greenhalgh,Alan K. Burnett,Jonathan Montgomery	2011	17
6	The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine Haematologica ·Elisabeth Walsby,Steven Coles,Steven Knapper,Alan K. Burnett	2010	45
7	Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party British Journal of Haematology ·Keith Wheatley,Anthony H. Goldstone,Tim Littlewood,Anne Hunter,Alan K. Burnett	2009	27
8	Acute Leukemia in Adolescents and Young Adults Seminars in Oncology ·Anjali S. Advani,Stephen P. Hunger,Alan K. Burnett	2009	34
9	The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial British Journal of Haematology ·Alan K. Burnett,Donald Milligan,Anthony P. Goldstone,A. G. Prentice,Mary‐Frances McMullin,Michael Dennis,E. Sellwood,Monica Pallis,Nigel H. Russell,Robert K. Hills,Keith Wheatley	2009	110
10	The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA Blood ·Alan K. Burnett,Robert K. Hills,Claire Green,Sarah Jenkinson,Kenneth Koo,Yashma Patel,Carol Guy,Amanda Gilkes,Donald Milligan,Anthony H. Goldstone,A. G. Prentice,Keith Wheatley,David C. Linch,Rosemary E. Gale	2009	83
11	Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts Haematologica ·Elisabeth Walsby,V. Walsh,Chris Pepper,Alan K. Burnett,Ken Mills	2008	72
12	FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia Blood ·Adam J. Mead,David C. Linch,Robert K. Hills,Keith Wheatley,Alan K. Burnett,Rosemary E. Gale	2007	230
13	Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial British Journal of Haematology ·Bronno van der Holt,Dimitri Breems,H. Berna Beverloo,Eva van den Berg,Alan K. Burnett,Pieter Sonneveld,Bob Löwenberg	2006	47
14	Optimized Retroviral Transduction Protocol Which Preserves the Primitive Subpopulation of Human Hematopoietic Cells Biotechnology Progress ·Alex Tonks,Amanda J. Tonks,Lorna Pearn,Zulkhairi Mohamad,Alan K. Burnett,Richard L. Darley	2005	15
15	Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia Biochemical and Biophysical Research Communications ·Barbara‐ann Guinn,Amanda Gilkes,E. L. Woodward,Nigel Westwood,Ghulam J. Mufti,David C. Linch,Alan K. Burnett,Ken Mills	2005	29
16	Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials. Blood ·Alan K. Burnett,Donald Milligan,Robert K. Hills,Anthony H. Goldstone,Archie Prentice,Keith Wheatley,David C. Webb,Brenda Gibson	2004	4
17	ACUTE MYELOID LEUKEMIA: TREATMENTOF ADULTS UNDER 60 YEARS PubMed ·Alan K. Burnett	2002	40
18	Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells Leukemia Research ·Angela Provitera McGlynn,Rose Ann Padua,Alan K. Burnett,Richard L. Darley	2000	10
19	Oncogenic RAS genes impair erythroid differentiation of erythroleukaemia cells Leukemia Research ·Farhad Zaker,Richard L. Darley,Ala Al Sabah,Alan K. Burnett	1997	11
20	Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS) Leukemia Research ·Gillian S. Masters,Paul Baines,Carol Tang,David Bowen,Alan K. Burnett	1995	7

About Alan K. Burnett

Alan K. Burnett is a scholar working on Hematology, Genetics and Immunology, having authored 35 papers that have together received 2.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (21 papers), Acute Lymphoblastic Leukemia research (11 papers), Chronic Lymphocytic Leukemia Research (6 papers), Retinoids in leukemia and cellular processes (6 papers), Chronic Myeloid Leukemia Treatments (5 papers), Multiple Myeloma Research and Treatments (3 papers), Neutropenia and Cancer Infections (3 papers) and Histone Deacetylase Inhibitors Research (3 papers). The work is most often cited by research in Hematology (1.7k citations), Genetics (501 citations) and Public Health, Environmental and Occupational Health (533 citations). Alan K. Burnett has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Robert K. Hills, Keith Wheatley, David C. Linch, Rosemary E. Gale, Anthony H. Goldstone, Richard L. Darley, Richard E. Clark, Alastair G. Smith, R. M. Hutchinson and Alex Tonks. Their work appears in journals such as Blood, Biochemical and Biophysical Research Communications and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact